Get the Stockscreener App
4.47
4.08%
-0.19
After Hours:
4.44
-0.03
-0.67%
Lexeo Therapeutics Inc stock is traded at $4.47, with a volume of 965.45K.
It is down -4.08% in the last 24 hours and down -5.89% over the past month.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
See More
Previous Close:
$4.66
Open:
$4.7
24h Volume:
965.45K
Relative Volume:
1.10
Market Cap:
$350.99M
Revenue:
$531.00K
Net Income/Loss:
$-99.96M
P/E Ratio:
-2.0393
EPS:
-2.1919
Net Cash Flow:
$-98.96M
1W Performance:
-1.76%
1M Performance:
-5.89%
6M Performance:
-40.72%
1Y Performance:
+8.23%
1-Day Range:
$4.40
$4.845
1-Week Range:
$4.40
$5.008
52-Week Range:
$3.91
$10.99
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc
Sector
Industry
Phone
(212) 547-9879
Address
345 PARK AVENUE SOUTH, NEW YORK
Compare LXEO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXEO
Lexeo Therapeutics Inc
|
4.47 | 365.91M | 531.00K | -99.96M | -98.96M | -2.1919 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Raymond James | Strong Buy |
| Nov-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-15-25 | Initiated | Guggenheim | Buy |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Jun-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-28-23 | Initiated | Chardan Capital Markets | Buy |
| Nov-28-23 | Initiated | JP Morgan | Overweight |
| Nov-28-23 | Initiated | Leerink Partners | Outperform |
| Nov-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-28-23 | Initiated | Stifel | Buy |
View All
Lexeo Therapeutics Inc Stock (LXEO) Latest News
Lexeo Therapeutics Inc (LXEO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lexeo Therapeutics Inc (LXEO) Balance Sheet - TradingKey
Lexeo Therapeutics Inc (LXEO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexeo Therapeutics Inc (LXEO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexeo Therapeutics Inc (LXEO) Cash Flow - TradingKey
TradingKey - TradingKey
LXEO|Lexeo Therapeutics Inc|Price:4.660|Chg%:-0.050 - TradingKey
Lexeo Therapeutics Inc (LXEO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexeo Therapeutics Inc (LXEO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexeo Therapeutics Inc (LXEO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexeo’s SUNRISE-FA 2 Trial Puts Gene Therapy for Rare Heart Disease in Investor Focus - TipRanks
Lexeo Therapeutics (LXEO) Faces Continued Selling Pressure as Shares Test Key Support LevelsSuperTrend Flip - dars.gov.et
What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple - Yahoo Finance
Lexeo Therapeutics (LXEO) Slips 4.55% as Stock Tests Support Near $4.58Channel Projection - dars.gov.et
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
Lexeo Therapeutics (LXEO) Slips 4.55% as Stock Tests Proximity to Key SupportZero Lag EMA - dars.gov.et
Lexeo Therapeutics Slips 5.3% as Biotech Volatility Weighs on LXEO SharesVolatility Surface - dars.gov.et
Lexeo Therapeutics (LXEO) Edges Higher as Key Support HoldsPassive Flow - dars.gov.et
Have Lexeo Therapeutics Insiders Been Selling Stock? - 富途牛牛
Stifel Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $17 - Moomoo
LXEOLexeo Therapeutics Inc Dividends - Finviz
Have Insiders Sold Lexeo Therapeutics Shares Recently? - simplywall.st
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? - Yahoo Finance
Lexeo Therapeutics CMO sells $98,592 in shares By Investing.com - Investing.com South Africa
Lexeo Therapeutics CMO sells $98,592 in shares - Investing.com
Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock By Investing.com - Investing.com Australia
Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock - Investing.com
Form 4 Lexeo Therapeutics Inc For: 1 July By Investing.com - Investing.com India
RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer - Stock Titan
Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale - Stock Titan
Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes - Stock Titan
Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale - Stock Titan
Form 144 Lexeo Therapeutics For: 1 July By Investing.com - Investing.com UK
LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity - Stock Titan
Form 144 Lexeo Therapeutics For: 1 July - Investing.com India
[144] Lexeo Therapeutics, Inc. SEC Filing - Stock Titan
LXEO (NASDAQ: LXEO) director files Form 144 proposing sale of 25,947 shares - Stock Titan
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Form 4 Lexeo Therapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Lexeo Shareholders Reelect Directors, Ratify KPMG Auditor - TipRanks
Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor - Stock Titan
Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70 - Stock Titan
Lexeo Therapeutics (LXEO) director receives 35,000 options at $4.70 - Stock Titan
Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 - Stock Titan
Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 strike - Stock Titan
Lexeo Therapeutics (LXEO) director receives grant of 35,000 stock options at $4.70 - Stock Titan
Lexeo Therapeutics, Inc. Actuals & Estimates (NASDAQ:LXEO) - TradingView
LXEO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView
Price to book forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO - TradingView
Lexeo Therapeutics Inc Stock (LXEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):